tiprankstipranks
Trending News
More News >
CompuGroup Medical SE (DE:COP)
XETRA:COP

CompuGroup Medical (COP) AI Stock Analysis

Compare
31 Followers

Top Page

DE

CompuGroup Medical

(XETRA:COP)

Rating:64Neutral
Price Target:
€23.50
▲(3.71%Upside)
CompuGroup Medical's stable financial performance, characterized by consistent revenue growth and strong cash generation, is a key strength. However, a high P/E ratio suggests overvaluation, offset by a robust dividend yield. Technical indicators imply a neutral market sentiment, contributing to an overall moderate stock evaluation.
Positive Factors
Organizational Growth
The new guidance for FY25 suggests organizational sales growth in the low-to-mid single-digit range, indicating a positive outlook for future expansion.
Negative Factors
Financial Performance
Adjusted EBITDA decreased by 20% year-over-year, reflecting a weakened profit margin.
Profitability Challenges
Profitability in the fourth quarter was impacted by ramp-up costs for larger projects and technology investments, resulting in a 20% year-over-year decrease in adjusted EBITDA.

CompuGroup Medical (COP) vs. iShares MSCI Germany ETF (EWG)

CompuGroup Medical Business Overview & Revenue Model

Company DescriptionCompuGroup Medical SE & Co. KGaA develops and sells software and information technology solutions for the healthcare sector worldwide. It operates in four segments: Ambulatory Information Systems (AIS), Pharmacy Information Systems (PCS), Hospital Information Systems (HIS), and Consumer & Health Management Information Systems (CHS). The AIS segment provides practice management software and electronic medical records for registered physicians, medical care centers, and physicians networks, as well as offers supplementary Internet and intranet solutions. The PCS segment provides administrative and billing-related software applications for pharmacies. Its software solution provides information and decision support to manage various aspects of supply chain for medication. The HIS segment provides clinical and administrative solutions for the inpatient sector. This segment serves acute care hospitals, rehabilitation centers, social services, multi-location hospital networks and regional care organizations, and medical laboratories. The CHS segment provides IT security services, data-based product offers, software interface for sharing of information, clinical decision-making support, and medication and treatment databases for healthcare service providers, as well as digital healthcare stock, consumer portals, and mobile apps. This segment also offers security solutions for healthcare providers. It serves pharmaceutical companies, health insurance companies, and other healthcare IT companies and consumers. The company was formerly known as CompuGroup Medical SE and changed its name to CompuGroup Medical SE & Co. KGaA in June 2020. CompuGroup Medical SE & Co. KGaA was founded in 1987 and is headquartered in Koblenz, Germany.
How the Company Makes MoneyCompuGroup Medical generates revenue primarily through the sale of software licenses, maintenance contracts, and professional services. The company offers its products through a subscription-based model, providing continuous software updates and support as part of its service. Key revenue streams include licensing fees from their healthcare IT solutions, recurring revenues from service contracts, and consulting services for software implementation and customization. Significant partnerships with healthcare institutions and governments further contribute to their earnings by expanding their market reach and enhancing their product offerings.

CompuGroup Medical Financial Statement Overview

Summary
CompuGroup Medical demonstrates steady revenue growth, strong operational efficiency with solid EBIT and EBITDA margins, and resilience in cash generation. However, challenges in enhancing net profitability and managing leverage remain.
Income Statement
70
Positive
CompuGroup Medical demonstrates steady revenue growth over the years, although recent periods show a slight decline in revenue. The company maintains solid EBIT and EBITDA margins, indicating operational efficiency. However, net profit margins are relatively low, suggesting potential challenges in managing bottom-line profitability.
Balance Sheet
65
Positive
The balance sheet reflects a moderate level of leverage with a debt-to-equity ratio that suggests reliance on debt financing. However, the equity ratio is stable, indicating a satisfactory level of equity financing. The return on equity is modest, pointing to moderate profitability relative to shareholder investment.
Cash Flow
75
Positive
CompuGroup Medical's cash flow statement shows positive free cash flow and an improving trend in operating cash flow, which exceeds net income, suggesting strong cash conversion capabilities. The free cash flow growth rate is positive, although fluctuations in capital expenditures may impact cash flow stability.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue1.16B1.15B1.19B1.13B1.03B837.26M
Gross Profit821.16M965.14M1.01B958.16M285.89M712.95M
EBITDA197.37M206.90M215.84M231.36M216.63M192.49M
Net Income27.00M34.60M45.92M73.41M68.97M73.19M
Balance Sheet
Total Assets2.02B1.97B1.90B1.94B1.79B1.57B
Cash, Cash Equivalents and Short-Term Investments128.64M107.61M64.54M90.96M107.63M75.61M
Total Debt826.65M879.99M766.94M786.47M741.31M554.54M
Total Liabilities1.37B1.32B1.23B1.27B1.18B926.84M
Stockholders Equity651.09M647.91M667.68M672.42M612.07M638.67M
Cash Flow
Free Cash Flow84.57M65.66M104.11M63.99M87.78M94.20M
Operating Cash Flow143.96M128.88M179.53M145.03M165.27M149.93M
Investing Cash Flow-108.83M-105.28M-124.33M-145.41M-163.98M-457.12M
Financing Cash Flow-35.70M18.81M-80.69M-16.36M30.15M338.07M

CompuGroup Medical Technical Analysis

Technical Analysis Sentiment
Positive
Last Price22.66
Price Trends
50DMA
22.15
Positive
100DMA
22.35
Positive
200DMA
19.75
Positive
Market Momentum
MACD
0.14
Negative
RSI
63.71
Neutral
STOCH
40.28
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:COP, the sentiment is Positive. The current price of 22.66 is above the 20-day moving average (MA) of 22.24, above the 50-day MA of 22.15, and above the 200-day MA of 19.75, indicating a bullish trend. The MACD of 0.14 indicates Negative momentum. The RSI at 63.71 is Neutral, neither overbought nor oversold. The STOCH value of 40.28 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DE:COP.

CompuGroup Medical Peers Comparison

Overall Rating
UnderperformOutperform
Sector (50)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
DECOP
64
Neutral
€1.19B33.825.26%4.43%-2.84%-24.28%
50
Neutral
kr5.18B11.75-82.66%10.10%36.04%27.80%
€1.39B40.7117.48%1.50%
€44.77M10.8324.14%3.86%
€1.23B37.4411.87%0.28%
€331.86M20.656.73%2.02%
$366.64M22.702.99%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
DE:COP
CompuGroup Medical
22.66
-1.14
-4.79%
GB:0NZY
Eckert & Ziegler Strahlen und Medizintechnik
66.80
25.97
63.61%
GB:0HI7
MeVis Medical Solutions
25.60
-5.60
-17.95%
GB:0FGL
NEXUS AG
70.70
17.37
32.57%
GB:0RAR
STRATEC Biomedical
27.07
-18.73
-40.90%
MEDOF
Medios AG
14.50
-2.80
-16.18%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jun 17, 2025